Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.

Cancer research - 15 Apr 2026

Tiriac Hervé, Engle Dannielle D

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies with near-universal KRAS mutation. Although KRASG12D and KRASG12V are predominant, KRASG12R is also prevalent in PDAC yet rare in other KRAS-driven cancers such as lung and colorectal adenocarcinoma, suggesting pancreas-specific selective pressures. Unlike other KRAS mutants, KRASG12R fails to productively engage key nodes that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pancreatic Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 41982125
DOI: 10.1158/0008-5472.CAN-25-5676

Genes

KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.PMID 41982125Read ↗

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Semantic proximity Read ↗

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read ↗

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progressionSemantic proximity Read ↗

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

The KRAS mutational spectrum and its clinical implications in pancreatic cancer.Semantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesisSemantic proximity Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.